INAB
- IN8bio, Inc.
()
Overview
Company Summary
IN8bio, Inc. (INAB) is a biotechnology company focused on developing innovative therapies for the treatment of solid tumor cancers. The company utilizes a proprietary technology platform that combines gene therapy with targeted immunotherapy to address the challenges associated with treating cancer.
IN8bio's approach is centered around engineering patients' immune cells to express particular genes that can enhance their ability to detect and eliminate cancer cells. By modifying these immune cells, the company aims to create a more targeted and effective treatment strategy that specifically targets the tumor while minimizing damage to healthy tissues.
The company's technology platform, known as Gamma Delta T cells (GDT), enables the genetic modification of a specific subset of immune cells called gamma-delta T cells. These cells play a crucial role in the body's immune response, and IN8bio is harnessing their natural abilities to fight cancer.
IN8bio is currently focused on developing therapies for various solid tumor cancers, including lung, breast, ovarian, and colorectal cancers, among others. The company's proprietary approach has the potential to provide a personalized and precise treatment option for patients suffering from these types of cancers.
Overall, IN8bio, Inc. is dedicated to advancing the field of cancer therapy through its innovative gene therapy and immunotherapy approaches, aiming to provide patients with more effective and targeted treatment options for solid tumor cancers.